oppenheimer apple - Search News

Apple, iPhone

Oppenheimer downgrades Apple, cites weakening iPhone sales and AI innovation worries

Apple is having it hard. Oppenheimer downgraded it from “outperform” to “perform” amidst weak sales. The reason behind this is that the tech giant is struggling to adapt to a competitive AI landscape.

Bloomberg L.P. · 1d

Apple Gets Another Downgrade on iPhone Risk Ahead of Results

Apple Inc. was downgraded to perform from outperform at Oppenheimer, in the latest sign of caution building ahead of the company’s results.

Business Insider · 1d

Apple (AAPL) Gets Downgraded on Reduced iPhone Sales Estimates

Investment firm Oppenheimer has downgraded tech giant Apple (AAPL) stock from Buy to Hold due to reduced estimates for iPhone sales over the

Apple, Wall Street

Finbold | Finance in Bold · 19h

Wall Street sets Apple stock price for next 12 months

Apple’s approach to AI spending continues to lag behind its "Magnificent Seven" peers, a strategy that's drawn mixed reactions from analysts.

Business Insider · 11h

Wall Street increasingly bearish on Apple ahead of earnings

Apple (AAPL) is scheduled to report results of the first fiscal quarter of FY25 after the market close on Thursday, January 30, with a

MarketWatch · 17h

Apple sentiment has soured. What that means ahead of earnings.

Even a disappointing outlook might not be the end of the world for Apple's stock, according to an Evercore ISI analyst. Evercore's Amit Daryanani pointed to "some concern around industry data indicating iPhone weakness.

1don MSN

Apple's multiple will have to fall 20% for me to be interested, says Oppenheimer's Martin Yang

Martin Yang, Oppenheimer senior analyst, joins 'Squawk on the Street' to discuss what Apple Intelligence is lacking that's ...

17h

Is Apple Intelligence getting the job done?

Investors were hoping that Apple Intelligence would drive a wave of iPhone upgrades. How's that playing out? This will be the first full quarter of results from Apple since the company's iPhone 16 ...

Apple downgraded, Rivian initiated: Wall Street's top analyst calls

Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Apple, iPhone

Apple, Wall Street

Trending now